By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Taiho Pharmaceutical Company Ltd. 

1-27 Kandanishiki-cho

Chiyoda-ku  Tokyo  101-8444  Japan
Phone: N/A Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Taiho Pharmaceutical Invests US $30 Million In Remiges Biopharma Fund, LP 7/23/2014 11:16:21 AM
Taiho Pharmaceutical's Lonsurf® (Trifluridine And Tipiracil Hydrochloride) Tablets Approved In Japan For Treatment Of Advanced Metastatic Colorectal Cancer 3/24/2014 6:32:25 AM
Response Genetics, Inc. Renews Agreement With Taiho Pharmaceutical to Provide Molecular Analyses for Cancer 7/17/2013 9:28:54 AM
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102 2/27/2013 9:32:07 AM
Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102 5/31/2012 12:28:08 PM
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102 7/22/2011 6:15:40 AM
Taiho Pharmaceutical's Teysuno(TM) (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer 3/15/2011 8:17:44 AM
Taiho Pharmaceutical: Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 12/17/2010 6:41:43 AM
Taiho Pharmaceutical Selects Medidata Solutions, Inc. Rave for Global Trials 7/28/2008 9:04:18 AM
Taiho Pharmaceutical and Sanofi-Aventis (France) (SASY.PA) Release: S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone 6/4/2007 2:47:24 PM
123
//-->